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Contrast-enhanced ultrasound (CEUS) is a relatively novel, but increasingly used, diagnostic 
imaging modality. In recent years, due to its safety, quickness, and repeatability, several studies 
have demonstrated the accuracy, specificity, and sensitivity of CEUS. The European Federation of 
Societies for Ultrasound in Medicine and Biology has recently updated the previous guidelines 
from 2012 for the use of CEUS in non-hepatic applications. This review deals with the clinical use 
and applications of CEUS for the evaluation of non-hepatic abdominal organs, focusing on renal, 
splenic, and pancreatic applications.
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Introduction
Contrast-enhanced ultrasound (CEUS) is a dynamic imaging technique based on intravenous injection 
or instillation into body cavities of an agent made up of microbubbles. During each exam, continuous 
insonation of the region of interest, with real-time evaluation of all phases, is performed. The 
microbubbles are excreted from the lung and the liver, making them safe for patients with a history 
of chronic renal insufficiency, dialysis, kidney transplant, and nephrectomy. Other advantages are 
that microbubbles do not contain iodine, have a very low rate of anaphylactoid reactions, do not use 
ionizing radiation, and are relatively inexpensive [1]. In the literature, several authors have stressed 
the important role of CEUS in the evaluation of liver disease, recommending its clinical use as a 
supplement to cross-sectional imaging in treatment planning, control, and monitoring of malignant 
liver lesions [2-4]. 
Unlike in Korea, the use of CEUS in Europe has only been approved for a limited number of non-
hepatic indications in adults [5]; but its numerous benefits, compared to its risks, has recently made 
it an emergent imaging technique for non-hepatic applications as well. For this reason, the European 
Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) has recently described 
and recommended several possible applications of CEUS for various conditions involving the 
gastrointestinal and genitourinary tract, pancreatic gland, main vessels, and superficial organs, such 
as the thyroid, lymph nodes, salivary glands, breasts, and joints [6].  
The ultrasonography (US) contrast agents currently used in diagnostic US of the liver are SonoVue, 
Definity/Luminity, and Sonazoid. In contrast to SonoVue, which is a pure intravascular agent without 
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an interstitial extravascular phase, Sonazoid is an intravascular 
agent, licensed only in Japan and South Korea, which can also be 
taken up by the Kupffer cells in the sinusoidal spaces, allowing both 
vascular-phase and Kupffer-phase images to be obtained [7,8].
Although studies have recently demonstrated the benefits of 
the use of US contrast agents in children, no US contrast agent 
manufactured today is registered for pediatric use in Europe 
and CEUS is still used off-label in pediatric patients [6,9,10]. 
SonoVuehas recently been approved by the United States Food 
and Drug Administration under the name of Lumason to be used in 
hepatic investigations and in assessments of vesico-ureteral reflux in 
children [6,11].
Kidney
US is the first-line imaging modality for evaluating kidney diseases. 
The use of a microbubble-based contrast agent permits a better 
assessment of microcirculation and perfusion of the kidney than 
Doppler US, with no risk of nephropathy [12].
Imaging Protocol and Normal Findings
During a renal study with CEUS, the following phases are described: 
first the arterial pedicle and cortex enhance in the cortical phase, 
which occurs 15-30 seconds after the injection, and then the 
cortex and medulla enhance together in the parenchymal phase 
(25 seconds to 4 minutes after the injection), which can also be 
divided into early (25 seconds to 1 minute) and late (1-4 minutes) 
components [6,12]. Because of the high cortical perfusion, a lower 
dose of contrast agent is used (typically 1-1.5 mL of SonoVue, 
compared with 2.4 mL in a typical liver study) to avoid obscuration 
of the deeper parts of the kidney [12]. 
Role of CEUS 
The majority of adult patients have at least 1 renal lesion, and 
many renal lesions are incidentally detected by imaging. Most renal 
lesions are benign simple cysts, but in other cases, they can be solid 
or mixed solid and cystic [13,14]. These masses require multiphasic 
contrast-enhanced renal imaging-specifically, contrast-enhanced 
computed tomography (CECT) or magnetic resonance imaging (MRI) 
with intravenous injection of iodinated contrast or gadolinium, 
respectively-in order to evaluate enhancement characteristics that 
often differ between benign and malignant lesions [15]. In this 
scenario, CEUS plays an important role both in the characterization 
of some indeterminate masses on computed tomography (CT) and 
MRI and as a valuable alternative tool in selected patients in whom 
iodinated contrast medium or gadolinium is contraindicated or when 
CT or MRI scans are otherwise deemed inappropriate [16]. According 
to the recent update of the EFSUMB guidelines, the indications for 
the use of CEUS in the kidneys are suspected vascular disorders 
(infarction, cortical necrosis), differentiating between tumors and 
pseudotumors, characterization and follow-up of complex cystic 
masses, identification of renal abscesses, and radiofrequency 
ablation of non-surgical masses [6,17]. CEUS plays a very important 
role in distinguishing between solid lesions and hyperdense cysts. In 
fact, hyperdense renal lesions on unenhanced CT (20-70 Hounsfield 
units [HU]) require correlation with conventional sonography, where 
they can frequently be confidently diagnosed as cystic. In less 
conclusive cases, CEUS may be an alternative imaging technique to 
demonstrate the absence or presence of vascular flow within the 
lesion, avoiding both the radiation dose and potential nephrotoxicity 
of iodinate agents used in CT scans and the risk of false negatives 
for hypovascular tumors [18,19].
Renal Lesions
Solid lesions
CEUS allows a detailed assessment of the neoplastic circulation 
and has the potential to differentiate malignant from benign renal 
lesions when they appear as hypoechoic [12,20].
CEUS is more sensitive than contrast-enhanced CT and MRI in 
detecting vascularity in hypovascular lesions [18], and it is also 
sensitive in identifying unenhancing cystic areas, necrosis, debris, 
and hemorrhagic foci in tumors that may be hard to detect on CECT 
and MRI, especially in small lesions [18].
On CEUS, renal tumors show different patterns of enhancement 
in comparison with the renal parenchyma in at least one phase. 
Renal clear cell carcinoma (RCC) usually shows hyperenhancement 
or isoenhancement, generally inhomogeneous, in the cortical 
phase, washout in the late phase, and perilesional rim-like 
enhancement [21], whereas papillary carcinoma tends to show less 
hyperenhancement, usually homogeneous, during the cortical phase 
[21,22]. 
Angiomyolipoma generally shows homogeneous isoenhancement 
or hypoenhancement and prolonged enhancement [23], but when 
it presents a hypoechoic rim, cystic component, or pseudocapsule, it 
may be difficult to differentiate from small (<3 cm) echogenic RCC 
[12].  Moreover, studies have recently demonstrated that tumors 
smaller than 3 cm may frequently show homogeneous enhancement 
on CEUS, regardless of the histologic subtype [23]. 
Renal oncocytomas cannot be differentiated from RCC because of 
their similar enhancement patterns [24].
Instead, solid renal tumors may be easily distinguished from 
pseudotumors, abscesses, and ischemic disorders of the kidneys, as 
pseudotumors remain isoechoic to the normal renal parenchyma 
in all phases, abscesses are seen as a non-enhancing area (solitary 
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or within areas of pyelonephritis), and infarcts appear as wedge-
shaped non-enhancing areas within an otherwise enhanced kidney [6].
Concerning solid renal lesions, several studies have evaluated 
the diagnostic accuracy of CEUS, compared with CT and MRI, for 
the differential diagnosis of benign and malignant renal lesions, 
applying both qualitative and quantitative features. Unfortunately, 
according to the literature and updated guidelines, CEUS cannot 
be used-either with qualitative or quantitative methods-to 
differentiate renal solid cancerous histotypes [17,20,23,25].
Cystic lesions
Cystic renal masses are common and can vary from simple to 
complex; the complexity of cysts may be due to hemorrhagic, 
infectious, or ischemic processes inside the lesion [26]. Around 10% 
of renal cell carcinomas appear as complex cystic renal masses [27]. 
In contrast to what their malignant appearance suggests, some 
cystic lesions can remain stable for a long time, while malignant 
cysts often need timely surgery. Consequently, accurate diagnosis is 
essential to guide clinical management. The Bosniak classification 
of renal cysts based on CT was first published in 1986 and modified 
in 1993 [28-30] in order to predict the risk of malignancy and 
establish treatment recommendations [31]. This classification system 
distinguishes five categories (1, 2, 2F, 3, and 4) of cystic renal 
masses according to the number of septa; the thickness of the cyst 
walls or septa; the enhancement of the septa, wall, nodule, or other 
solid components; and the presence of calcifications [26,28,32-
34]. The Bosniak classification has been applied using CEUS and 
a classification system similar that for CECT [15,32] has been 
proposed [35,36]. In clinical practice, the greatest difficulty arises 
for all modalities in differentiating among categories II, IIF, and III 
and in recommending surgery or conservative follow-up [32,37,38]. 
Several studies have investigated the accuracy of CEUS compared 
with CECT and MRI. A recent meta-analysis conducted by Lan et al. 
[39] revealed that the sensitivity of CEUS was higher than that of 
CECT, while the specificity of CEUS was slightly lower than that of 
CECT. The high spatial resolution of CEUS permits the detection of 
more septa, thickened walls and septa, and more solid components 
than is possible using CT [37,38,40]. Moreover, evaluation in 
real time can also help in the assessment of cysts with several 
confluent septa that may mimic a solid mass [15]. Because of the 
characteristic scattering property of microbubbles, the tiny capillaries 
that feed hair-line septa can also be revealed. This fact explains why 
several authors have found CEUS to show higher sensitivity than 
CT in depicting the cystic wall and septa vascularity [15,38,40-
43]. However, minimal septal enhancement can also occur in benign 
renal cystic lesions, and many authors have reported that CEUS can 
upgrade some cystic masses compared with CT when using the 
Bosniak classification system [43-45]. Recently, Zhou et al. [37] 
performed a meta-analysis comparing the diagnostic efficacy of 
CEUS with that of MRI for cystic renal masses, and suggested that 
CEUS is equivalent to MRI in the diagnostic value for cystic renal 
masses, although it has higher sensitivity and lower specificity than 
MRI. 
Summary
The most interesting field of renal CEUS applications regards the 
characterization of renal cysts (Fig. 1). In clinical practice, CEUS 
may be used to characterize and follow-up complex cysts found 
on conventional US and to refine the correct Bosniak category of 
indeterminate renal cysts on CECT. Due to its high sensitivity and 
low specificity, CEUS should always be used in combination with 
CECT in order to improve the lesion detection rate and to decrease 
the misdiagnosis rate. For solid lesions, CEUS has recently been 
recommended to evaluate low- to moderate-risk lesions in patients 
who have absolute or relative contraindications to CECT or MRI and 
as a secondary test for indeterminate lesions (small lesions or with a 
threshold of 15-20 HU) on CECT or MRI [25].
Spleen
The splenic parenchyma is always evaluated during abdominal US. 
The location, homogeneous parenchyma, and small size of the 
spleen make it well suited for CEUS examinations. 
Imaging Protocol and Normal Findings
Due to the particular vascularization of the spleen in the early 
phase after the injection of microbubbles (after 12-18 seconds), an 
inhomogeneous opacification (a "zebra-striped" pattern) may be 
seen [46]. This heterogeneous appearance creates a potential pitfall 
to interpretation, especially for inexperienced practitioners, and 
makes it difficult to identify lesions that are not accurately located 
on gray-scale images [47]. After 60 seconds, the parenchyma 
enhances homogeneously with late-phase enhancement. The spleen, 
like the liver, has the property of retaining microbubbles, resulting 
in persistent late-phase enhancement that usually persists for 5-7 
minutes [6,46].
Role of CEUS in Splenic Disease 
According to the recent update of the EFSUMB guidelines, CEUS can 
be used to evaluate abnormal splenic size and to identify infarctions, 
ectopic splenic tissue, and splenic lesions. CEUS is particularly 
recommended to distinguish simple cysts from abscesses in selected 
cases and focal solid benign lesions from malignant ones, especially 
when echo-poor on US [6]. The spleen is frequently involved in 
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lesions of the spleen are most common benign vascular tumors 
(hemangiomas or hamartomas). They often show isoenhancement 
or hyperenhancement in the arterial phase, rarely followed by slow, 
modest, and incomplete washout [6,47]. Instead, focal, echo-poor, 
splenic lesions are usually malignant and represent a diagnostic 
challenge [47]. They are more frequently multiple, fast-growing, and 
present inhomogeneous enhancement with necrotic areas in the 
arterial phase and rapid and complete washout in the early and late 
phases [47,51]. The presence of irregular intralesional vessels and a 
'dotted' appearance in the parenchymal phase are other features of 
malignant lesions [50]. 
Malignant splenic lesions are almost always either lymphomas or 
metastases [47]. 
Non-lymphomatous metastases are very rare and represent a 
sign of advanced disease of melanoma, breast cancer, and lung 
cancer. They mainly show inhomogeneous hypoenhancement in the 
arterial phase and a rapid wash-in and rapid wash-out pattern with 
patients with intra-abdominal trauma, and CEUS could play an 
interesting and emergent role in the detect and follow-up of splenic 
traumatic lesions [48,49]. 
In any case, knowledge of the patient's clinical presentation, 
past medical history, laboratory tests, and previous imaging is often 
essential for a differential diagnosis [50]. 
Splenic Tumors
An early and precise differential diagnosis between benign and 
malignant focal splenic lesions can provide a timely and rational 
treatment modality for the clinical choice between invasive and 
noninvasive management.
Only a few CEUS studies in the literature have investigated splenic 
tissue [51]. According to these studies, the sensitivity, specificity, and 
accuracy of CEUS are all higher than those of US. Moreover, CEUS 
showed comparable performance to positron emission tomography 
computed tomography (PET-CT) diagnosis [51]. Small echogenic 
Fig. 1. Contrast-enhanced ultrasonography (CEUS) study of the 
kidney of a 67-year-old man with a renal cyst. 
A. Doppler ultrasonography shows a solid hypoechoic mass in the 
upper pole of the kidney with Doppler intralesional artifacts. B. CEUS 
shows a completely avascular complex renal cyst. 
A
B
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a contrast agent [50,51]. Late-phase imaging is very important for 
depicting the microcirculation in areas of viable tumors that may be 
mistaken for necrosis, which is essential when assessing response to 
chemotherapy [50]. CEUS is used to characterize these masses only 
when CT and/or MRI and PET are contraindicated or inconclusive. 
Splenic lymphoma is usually a manifestation of systemic lymphoma, 
mostly non-Hodgkin disease, while primitive lymphoma of the 
spleen is rare [46]. On US imaging, splenic lymphoma may appear 
as small nodules or miliary infiltrations, typical of low-grade 
lymphoma, or as large masses and bulky infiltrative disease, found 
in high-grade lymphoma [46,50]. Lesions are typically hypoechoic 
compared with normal splenic parenchyma; after therapy, recurrent 
lesions frequently show a heterogeneous or 'target' appearance 
[46,51,52]. In the arterial phase, they may be homogeneously 
isoenhancing or hypoenhancing relative to the splenic parenchyma, 
with internal irregular vessels, while in the parenchymal phase they 
become hypoenhancing, due to rapid washout [50]. In a recent 
prospective study, Picardi et al. [53] compared CEUS and fluorine-18 
fluorodeoxyglucose (FDG)-PET in order to detect nodular infiltration 
in the spleen of patients with newly diagnosed Hodgkin lymphoma. 
They evaluated 100 adult patients indicated for pre-treatment 
staging according to the Ann Arbor system, and demonstrated that 
CEUS was more sensitive in identifying splenic nodules positive for 
lymphoma than CT and FDG-PET were. This was valid both for small 
nodules (<1 cm) and for larger ones (>1.1 cm), and this finding 
led to a change in Ann Arbor staging system. Therefore, even in the 
absence of histologic proof, CEUS should be recommended as a part 
of the diagnostic work-up to stage patients with Hodgkin lymphoma 
in order to avoid the risk of understaging and undertreatment [53]. 
Splenic Trauma 
In a prospective multi-centric study, Catalano et al. [54] evaluated 
156 adult patients with clinical and abdominal suspicion of blunt or 
penetrating abdominal trauma, considering CT and surgery as the 
reference standards. In accordance with the current literature, they 
found that CEUS may improve the detection and severity assessment 
of abdominal injuries [48,54-57]. In particular, for the spleen, 
they demonstrated that the sensitivity, specificity, and accuracy of 
CEUS were 93%, 99%, and 97% higher, respectively, than those of 
baseline US [54]. Comparable results were presented by Sessa et 
al. in a study of 256 patients with low-energy isolated abdominal 
trauma. They evaluated the accuracy of CEUS and demonstrated 
that, in these patients, US should be replaced by CEUS as the first-
line approach, because it shows a high sensitivity in both lesion 
detection and grading [58].
The venous phase is the most accurate for detecting traumatic 
lesions of the spleen [48].   
On the basis of the distribution of contrast material (homogeneous, 
heterogeneous, or absent) CEUS can identify parenchymal injuries, 
including contusions, lacerations, hematomas, bleeding, infarcts, 
and arteriovenous fistulas [57]. It should be used after the Focused 
Assessment with Sonography in Trauma (FAST) protocol or US, 
especially when the baseline US detects peritoneal/retroperitoneal 
fluid but fails to identify organ injury and/or demonstrates subtle 
parenchyma changes, or in cases of negative US findings with 
persistent laboratory suspicion in hemodynamically stable patients 
with a history of low-energy trauma [48,54,57,59].
Pseudoaneurysm is a rare complication of splenic trauma, but 
its identification is essential to avoid delayed splenic rupture. It is 
seen as well-delineated anechoic lesion on US and as an area of 
hyperenhancement in arterial-phase lesions on CEUS [51]. 
Summary
CEUS may significantly improve the accuracy of the detection and 
characterization of focal splenic lesions, especially malignant ones 
(Fig. 2). Concerning malignant lesions, the differential diagnosis 
between lymphoma and metastases is impossible on the basis 
of splenic CEUS appearance alone, although necrosis is more 
commonly seen in metastatic disease [50]. 
CEUS could play a valuable role in selected patients with 
abdominal trauma for the diagnosis and follow-up of splenic 
injuries; for unstable trauma patients; for cases of abdominal 
trauma in which CECT is contraindicated, failed, or unclear; and in 
monitoring of conservatively treated injuries [49,54]. 
CT should instead be reserved for cases of severe trauma with 
clinical suspicion of multiorgan lesions and cases with inconclusive 
CEUS findings [59].
Fig. 2. Contrast-enhanced ultrasonography study of the spleen 
of a 60-year-old woman with splenic lymphoma. Multiple splenic 
hypoechoic hypovascular malignant nodules can be seen, with a 
final diagnosis of lymphoma.
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Pancreas
CEUS of the pancreas leads to a major improvement in the 
diagnostic accuracy of US, which is usually applied in the initial 
evaluation of pancreatic diseases. When a pancreatic lesion, 
frequently incidental, is detected on US, an immediate differential 
diagnosis is essential for appropriate management. 
Imaging Protocol and Normal Findings
The blood supply of the pancreas is entirely arterial, so that 
enhancement of the gland begins almost together with aortic 
enhancement. In a pancreatic CEUS study, it is possible to 
distinguish an arterial phase (15-20 seconds after the microbubble 
injection), in which parenchymal enhancement may be seen, and 
a portal venous phase (from 30 to 120 seconds after injection), 
characterized by enhancement of the portal vein. During the late 
phase (about 120 seconds after injection) a complete evaluation 
of the liver should be performed, in order to identify possible 
metastatic lesions [60,61]. 
Role of CEUS
CEUS is a safe and accurate imaging method for differentiating solid 
from cystic pancreatic tumors and solid tumors from pseudo-tumor 
masses; doing so influences the choice of further examinations and 
allows a faster diagnosis to be obtained [62]. 
According to the most recent EFSUMB guidelines, CEUS can be 
used to distinguish between ductal pancreatic adenocarcinoma, 
which represents the most common primary malignancy of the 
pancreas [6,63], and pancreatic neuroendocrine tumor [6]. 
Among cystic pancreatic lesions, CEUS can distinguish cystic 
tumors from pseudocysts and detect the presence of vascular or 
avascular (necrotic) components in cystic lesions. Furthermore, CEUS 
is recommended for the follow-up of indeterminate pancreatic cysts 
and necrotizing pancreatitis [6].
Solid Pancreatic Tumors
On CEUS, pancreatic adenocarcinoma typically appears as a 
hypoenhancing mass compared to the surrounding parenchyma 
[64-68] and shows minimal enhancement in all the dynamic 
phases, because of its intense desmoplastic reaction with relatively 
poor mean vascular density and perfusion [69]. In the Pancreatic 
Multicenter Ultrasound Study (PAMUS) meta-analysis, a high 
accuracy of CEUS in characterizing pancreatic masses was reported, 
as solid pancreatic lesions were correctly characterized in respect 
to pathology with an accuracy of 91.7% and pancreatic ductal 
adenocarcinoma was correctly characterized with an accuracy 
of 87.8% [70]. In the literature, a specificity close to 100% for 
transabdominal CEUS diagnosis of ductal adenocarcinoma, with 
a sensitivity of 90%, has been reported [71,72]. Recently, a meta-
analysis was conducted with the aim of evaluating the role of 
CEUS in differentiating among pancreatic lesions. The authors 
reported a sensitivity of 89% and specificity of 84% for CEUS in the 
differentiation between ductal adenocarcinoma from non-ductal 
adenocarcinoma and a sensitivity of 95% and a specificity of 72% 
of CEUS in distinguishing neoplastic from non-neoplastic lesions [73]. 
According to the European Neuroendocrine Tumor Society (ENETS) 
Consensus Guidelines from 2012, CEUS is considered an alternative 
imaging method to diagnose pancreatic neuroendocrine tumors and 
to accurately assess the liver staging of the disease [74].
Cystic Pancreatic Lesions
Cystic lesions of the pancreas include a large variety of lesions, 
with different etiology and biology, each requiring a different 
management strategy [75,76]. Therefore, the evaluation of a 
pancreatic cystic tumor should enable differentiation between 
benign and malignant lesions [77]. 
Mucinous cystic neoplasms (MCNs) represent about 10% of all 
cystic pancreatic lesions [78] and include mucinous neoplasms with 
low-grade dysplasia (MCN) and mucinous cystadenocarcinoma. 
MCN is a benign lesion with a high malignant potential [79], 
and surgical resection is required in all cases. As stressed by the 
authors of new EFSUMB guidelines, thanks to the microbubble-
specific software that deletes all background signals and only 
shows the signal of the blood-pool contrast agent, CEUS can 
clearly demonstrate the micro-vascularization of septa and solid 
components of cystic pancreatic lesions, improving the differential 
diagnosis between mucinous cystic tumors and pseudocysts 
[64,80]. Pancreatic pseudocysts are persistent, late, peri-pancreatic 
collections that often develop after the onset of acute pancreatitis. 
They present a thin encapsulating wall, contain only fluid or fluid 
mixed with non-vascularized debris, and characteristically do not 
enhance in any phase on CEUS [70,80,81]. The reported sensitivity 
and specificity of CEUS in characterizing pseudocysts is very high 
[82].
Intraductal papillary mucinous neoplasms (IPMNs) are a group 
of exocrine mucin-producing tumors that spread into the main 
pancreatic duct and/or its collateral branches. They often show 
benign behavior, but they sometimes present solid components 
(perfused nodules) and a high malignant potential. Unfortunately, 
CEUS is not able to demonstrate communication with the ductal 
system, which is essential for the final diagnosis of IPMN, but it may 
be helpful for differentiating between perfused (nodules) and non-
perfused (mucin plugs) areas [81,83,84]. 
Serous cystadenoma (SCA) is a benign cystic tumor, with a 
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typical lobulated microcystic honeycomb architecture, thin wall, 
and thin multiple septa orientated toward the center [77], that 
never communicates with the main pancreatic duct [85], and is well 
demonstrated on magnetic resonance cholangiopancreatography 
[86]. The absence of communication with the main pancreatic 
duct is not demonstrable by US or CEUS [81]. SCAs are typically 
hypervascular and, therefore, hyperenhancing on CEUS, since the 
septa are composed of abundant sub-epithelial micro- and macro-
vessels, and especially when the cysts are small, they may mimic a 
solid lesion [76,87,88]. 
Acute and Chronic Pancreatitis
In acute pancreatitis, CEUS is an alternative imaging method for 
diagnosing mild and severe forms that, due to hyperemia, appear 
hypervascularized [64] and for delineating parenchymal necrosis in 
cases of severe acute pancreatitis, which appears as non-enhanced 
lesions, with a high accuracy [89]. Due to the lack of a panoramic 
view, CEUS may not substitute for the first CT examination for 
staging acute pancreatitis. However, it may be used in follow-up of 
acute pancreatitis, reducing the number of CT examinations [89]. 
Within the category of chronic pancreatitis, autoimmune 
pancreatitis is a rare disorder of presumed autoimmune etiology 
that accounts for up to 10% of chronic pancreatitis cases [90]. 
This inflammatory process shows three patterns of distribution: 
focal, multifocal, and diffuse. The focal pattern is less common than 
diffuse one, but it often involves the pancreatic head and may be 
confused with ductal adenocarcinoma. In clinical practice, CEUS 
may play an important role in differentiating these 2 entities. A 
Fig. 3. Contrast-enhanced ultrasonography (CEUS) study of the 
pancreas of a 56-year-old man with a solid pancreatic tumor.
A. On ultrasonography, an incidental isoechoic small lesion can 
be seen in the body of the pancreas, causing dilation of the main 
pancreatic duct. B. CEUS after the injection of microbubbles enabled 
an immediate diagnosis of pancreatic ductal adenocarcinoma 
because the lesion was markedly hypovascular in all phases.
A
B
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recent retrospective study of Dong et al. [91] reported that on CEUS, 
autoimmune pancreatitis displayed focal or diffuse isoenhancement 
(86.6%), in comparison to the surrounding parenchyma in the 
arterial phase and hyperenhancement (65%) or isoenhancement 
(35%) in the late phase, in contrast to ductal adenocarcinoma, 
which appeared hypoenhancing (93.7%) in all phases of the study.  
Summary
CEUS is very useful for diagnosing pancreatic tumors and for 
characterizing and differentiating ductal adenocarcinoma (Fig. 
3) from other pancreatic lesions, such as neuroendocrine tumors 
or focal pancreatitis [73]. It may help to define the size and the 
margins of pancreatic lesions, and therefore may be useful for 
guiding pancreatic biopsies [92]. Furthermore, with the use of CEUS, 
changes in pancreatic tumor vascularization during chemotherapy 
can be documented [93].
CEUS can be used to characterize cystic pancreatic lesions, and it 
is recommended for the follow-up of borderline cystic lesions, if well 
visualized on US, in order to reduce the use of MRI [94]. 
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